Citations

Clear

4 citation(s) found for "Goyal, Abhishek".

“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”
Fero, Henri , Gjika, Frenki , Faccin, Ester , Borré, Carla Isabel, Paparisto, Piro, Trako, Kristi, Alabbas, Fahad , Alsultan, Abdulrahman S. , Goyal, Abhishek

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6872-6872

10.1182/blood-2025-6872 Get It

Abstract Background: Philadelphia chromosome–negative (Ph–) ALL is a genetically heterogeneous entity defined by recurrent cytogenetic and molecular aberrations that shape its clinical trajectory and prognosis. Historically poor outcomes in adults prompted significant changes in therapeutic approaches over the past decade, resulting in improved survival. Currently, blinatumomab is a bispecific T-cell engager targeting CD19 in leukemic cells and CD3 on T Lymphocytes. It has shown significant results in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, its role in the frontline treatment of Philadelphia chromosome–negative (Ph–) B-ALL, particularly in combination with chemotherapy, is continuously being explored. Objective: Our purpose is to evaluate the efficacy of blinatumomab-based frontline regimens in adolescents and adults with newly diagnosed Ph– B-ALL through a systematic review and meta-analysis of proportions. Methods: We systematically searched PubMed, Embase, and Cochrane from inception through May 2025. Eligible studies included adolescents or adults with a cut off age of 15 years old, with newly diagnosed Ph– B-ALL where blinatumomab was used in the induction phase, consolidation phase, or both. Primary outcomes were complete remission (CR), measurable residual disease (MRD) negativity, and 3-year overall survival (OS). Random-effects proportional meta-analyses were conducted using logit or Freeman–Tukey transformations. Risk of bias was assessed using RoB 2 for Randomized Controlled Trials and ROBINS-I for prospective trials. Subgroup analysis was performed, dividing subgroups by phase of Blinatumomab utilization; either induction, consolidation or both. To tackle heterogeneity in the MRD pooled results, we conducted a Meta-regression to evaluate the link between different treatment phases and sample sizes. Results: Thirteen studies (n = 878 patients) met the inclusion criteria. The pooled CR rate after induction-phase blinatumomab was 78% (95% CI: 71–85%; I² = 21.2%). The pooled MRD negativity rate was highest in the induction-only group, at 90% (95% CI: 83%–95%), with no significant heterogeneity (I² = 0%). The consolidation group showed a pooled MRD negativity rate of 88% (95% CI: 75%–96%), though heterogeneity was substantial (I² = 74.2%, p = 0.0087). For patients treated during both induction and consolidation, the pooled MRD negativity rate was 89% (95% CI: 82%–94%), also with no observed heterogeneity (I² = 0%). The overall pooled MRD negativity rate across all ten studies was 89% (95% CI: 84%–93%), using a random-effects model with Freeman–Tukey double arcsine transformation. A meta-analysis of four studies reporting 3-year overall survival (OS) following frontline blinatumomab-based therapy was performed, stratified by treatment phase. In the consolidation subgroup, the pooled 3-year OS was 83% (95% CI: 76%–88%), with no heterogeneity (I² = 0%, p = 0.4032). In contrast, for patients treated during both induction and consolidation, the pooled 3-year OS was 52% (95% CI: 22%–81%), with substantial heterogeneity (I² = 88.6%, p < 0.0001). Conclusions: Blinatumomab-based regimens in the frontline setting are associated with high MRD clearance and complete remission rates, particularly when used during induction or consolidation. However, the predominance of non-randomized studies, small sample sizes, and heterogeneity in MRD assessment limit definitive conclusions. Prospective randomized trials are needed to clarify the optimal integration of blinatumomab in frontline Ph– B-ALL therapy.
Deciphering the Interactions of SARS-CoV-2 Proteins with Human Ion Channels Using Machine-Learning-Based Methods
Munjal, Nupur S., Sapra, Dikscha , Parthasarathi, Kaushik , Goyal, Abhishek , Pandey, Akhilesh , Banerjee, Manidipa , Sharma, Jyoti , Pandey, Akhilesh , Parthasarathi, K. T. Shreya

Mayo Clinic

Pathogens | February 17, 2022 | Volume: 11 | Issue: 2 | Pages: 259

10.3390/pathogens11020259 | PMID 35215201 Get It

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accountable for the protracted COVID-19 pandemic. Its high transmission rate and pathogenicity led to health emergencies and economic crisis. Recent studies pertaining to the understanding of the molecular pathogenesis of SARS-CoV-2 infection exhibited the indispensable role of ion channels in viral infection inside the host. Moreover, machine learning (ML)-based algorithms are providing a higher accuracy for host-SARS-CoV-2 protein–protein interactions (PPIs). In this study, PPIs of SARS-CoV-2 proteins with human ion channels (HICs) were trained on the PPI-MetaGO algorithm. PPI networks (PPINs) and a signaling pathway map of HICs with SARS-CoV-2 proteins were generated. Additionally, various U.S. food and drug administration (FDA)-approved drugs interacting with the potential HICs were identified. The PPIs were predicted with 82.71% accuracy, 84.09% precision, 84.09% sensitivity, 0.89 AUC-ROC, 65.17% Matthews correlation coefficient score (MCC) and 84.09% F1 score. Several host pathways were found to be altered, including calcium signaling and taste transduction pathway. Potential HICs could serve as an initial set to the experimentalists for further validation. The study also reinforces the drug repurposing approach for the development of host directed antiviral drugs that may provide a better therapeutic management strategy for infection caused by SARS-CoV-2.
Deciphering the interactions of SARS-CoV-2 proteins with human ion channels using machine learning-based method
Munjal, Nupur S., Sapra, Dikscha , Goyal, Abhishek , Parthasarathi, Kaushik , Pandey, Akhilesh , Banerjee, Manidipa , Sharma, Jyoti , Pandey, Akhilesh , Parthasarathi, K.T. Shreya

Mayo Clinic

No container title available | August 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-622770/v2 Get It

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the worldwide COVID-19 pandemic which began in 2019. It has a high transmission rate and pathogenicity leading to health emergencies and economic crisis. Recent studies pertaining to the understanding of the molecular pathogenesis of SARS-CoV-2 infection exhibited the indispensable role of ion channels in viral infection inside the host. Moreover, machine learning (ML)-based algorithms are providing higher accuracy for host-SARS-CoV-2 protein-protein interactions (PPIs). In this study, predictions of PPIs of SARS-CoV-2 proteins with human ion channels (HICs) were performed using PPI-MetaGO algorithm. The PPIs were predicted with 82.71% accuracy, 84.09% precision, 84.09% sensitivity, 0.89 AUC-ROC, 65.17% Matthews correlation coefficient (MCC) score and 84.09% F1 score. Thereafter, PPI networks of SARSCoV-2 proteins with HICs were generated. Furthermore, biological pathway analysis of HICs interacting with SARS-CoV-2 proteins showed the involvement of six pathways, namely inflammatory mediator regulation of transient receptor potential (TRP) channels, insulin secretion, renin secretion, gap junction, taste transduction and apelin signaling pathway. Our analysis suggests that transient receptor potential cation channel subfamily M member 4 (TRPM4), transient receptor potential cation channel subfamily A member 1 (TRPA1), gap junction protein alpha 1 (GJA1), potassium calcium-activated channel subfamily N member 4 (KCNN4), acid sensing ion channel subunit 1 (ASIC1) and inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) could serve as an initial set to the experimentalists for further validation. Additionally, various US food and drug administration (FDA) approved drugs interacting with the potential HICs were also identified. The study also reinforcesthe drug repurposing approach for the development of host directed antiviral drugs.
Deciphering the interactions of SARS-CoV-2 proteins with human ion channels using machine learning-based method
Munjal, Nupur S., Sapra, Dikscha , Goyal, Abhishek , Parthasarathi, Kaushik , Banerjee, Manidipa , Parthasarathi, K.T. Shreya, Pandey, Akhilesh , Sharma, Jyoti

Mayo Clinic

No container title available | June 16, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-622770/v1 Get It

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the worldwide COVID-19 pandemic which began in 2019. It has a high transmission rate and pathogenicity leading to health emergencies and economic crisis. Recent studies pertaining to the understanding of the molecular pathogenesis of SARS-CoV-2 infection exhibited the indispensable role of ion channels in viral infection inside the host. Moreover, machine learning-based algorithms are providing higher accuracy for host-SARS-CoV-2 protein-protein interactions (PPIs). In this study, predictions of PPIs of SARS-CoV-2 proteins with human ion channels (HICs) were performed using PPI-MetaGO algorithm. The PPIs were predicted with 82.71% accuracy, 84.09% precision, 84.09% sensitivity, 0.89 AUC-ROC, 65.17% MCC score and 84.09% F1 score. Thereafter, PPI networks of SARS-CoV-2 proteins with HICs were generated. Furthermore, biological pathway analysis of HICs interacting with SARS-CoV-2 proteins showed the involvement of six pathways, namely inflammatory mediator regulation of TRP channels, insulin secretion, renin secretion, gap junction, taste transduction and apelin signaling pathway. The inositol 1,4,5-trisphosphate receptor 1 (ITPR1) and transient receptor potential cation channel subfamily A member 1 (TRPA1) were identified as potential target proteins. Various FDA approved drugs interacting with ITPR1 and TRPA1 are also available. It is anticipated that targeting ITPR1 and TRPA1 may provide a better therapeutic management of infection caused by SARS-CoV-2. The study also reinforces the drug repurposing approach for the development of host directed antiviral drugs.